Details of the Drug Combination

General Information of Drug Combination (ID: DCH3W3Y)

Drug Combination Name
Indazole derivative 5 DFN-15
Indication
Disease Entry Status REF
Adult T acute lymphoblastic leukemia Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R DFN-15   DM3BF9B
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: MOLT-4
Zero Interaction Potency (ZIP) Score: 6.38
Bliss Independence Score: 8.66
Loewe Additivity Score: 8.86
LHighest Single Agent (HSA) Score: 10.23

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of DFN-15
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 3 [2]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DCGG6OO SR Investigative [1]
Chronic myelogenous leukemia DCMO2OW K-562 Investigative [1]
Carcinoma DCYTCR5 MCF7 Investigative [4]
Adenocarcinoma DCQI8M3 HT29 Investigative [5]
Cutaneous melanoma DCUAPXD SK-MEL-28 Investigative [5]
High grade ovarian serous adenocarcinoma DC8PO7S OVCAR-5 Investigative [5]
High grade ovarian serous adenocarcinoma DCETGFL OVCAR-8 Investigative [5]
High grade ovarian serous adenocarcinoma DCGPRM3 NCI\\/ADR-RES Investigative [5]
Lung adenocarcinoma DCX0IL5 HOP-62 Investigative [5]
Melanoma DCT0GME UACC-257 Investigative [5]
Melanoma DC32L2P MALME-3M Investigative [5]
Non-small cell lung carcinoma DCWW6BL HOP-92 Investigative [5]
Ovarian serous cystadenocarcinoma DC0V8ZE SK-OV-3 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.